CoChat

INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

PURPOSE: We evaluated the incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. We also assessed the predictive role of bone turnover markers determined at baseline. MATERIALS AND METHODS: A total of 112 patients were consecutively enrolled in our study from July 1990 to July 1998 and followed until death or the last followup. Bone pain, disease extent in bone, serum prostate specific antigen, hemoglobin, and a panel of bone formation and resorption markers were assessed at baseline before any second line treatment. RESULTS: Skeletal complications in 34 patients (30.3%, estimated yearly incidence 12.3%) involved vertebral deformity or collapse requiring spinal orthosis in 20 (17.9%), spinal cord compression in 7 (6.2%), pathological bone fracture in 10 (8.9%), symptomatic hypercalcemia in 1 (0.9%) and symptomatic hypocalcemia in 1 (0.9%). Median time to the evidence of the initial skeletal complication was 9.5 months. These adverse events did not influence overall survival. At baseline patients with eventual skeletal complications had greater bone pain (p = 0.02), a heavier tumor load in bone (p = 0.005), lower performance status (p = 0.05), and higher serum alkaline phosphatase (p <0.02) and urinary deoxypyridoline (p <0.05) than their counterparts. Multivariate analysis revealed that only urinary deoxypyridinoline was independently associated with the onset of these events (p <0.02). The scatterplot of urinary deoxypyridinoline values in patients with and without skeletal complications enabled us to detect a cutoff of 38 pM./mM. for predicting 51% of skeletal events with only an 8% false-positive rate. CONCLUSIONS: Skeletal complications are common in patients with prostate cancer and hormone refractory disease. Bone loss is the major cause of onset. Baseline deoxypyridinoline at the cutoff point noted had moderate sensitivity but high specificity for predicting these adverse skeletal events.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(05)67149-2

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 213

Metadata

Authors
BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A.
Affiliations
Ospedale San Luigi Gonzaga (IT)
Venue
Journal of Urology
Published
2000-10
Volume
164
Issue
4
Pages
1248-1253
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2159622173
Cited by
212
References
33
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 10
FWCI
6.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Journal of Urology (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
skeletal complications, bone metastatic prostate cancer, castration-resistant prostate cancer, bone turnover markers, urinary deoxypyridinoline, bone resorption, bone formation, pathological fracture, spinal cord compression, vertebral collapse, alkaline phosphatase, predictive biomarkers, bone pain
MeSH terms
Aged, Aged, 80 and over, Alkaline Phosphatase, Amino Acids, Bone Neoplasms, Bone Resorption, Calcium, Evaluation Studies as Topic, Humans, Male, Middle Aged, Prostatic Neoplasms, Regression Analysis, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE. https://app.cochat.ai/papers/10.1016/s0022-5347(05)67149-2
The paper
BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A. (2000). INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)67149-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.